Summary

The global biological safety cabinet market is anticipated to grow from USD 0.26 billion in 2026 to USD 0.36 billion by 2031, reflecting a CAGR of 6.6%. The global biological safety cabinet market is anticipated to grow steadily, supported by increasing investments in pharmaceutical and biopharmaceutical research, expansion of clinical and academic laboratories, and growing requirements for safe handling of infectious and hazardous biological materials. Demand is further supported by the development of vaccines, biologics, cell and gene therapies, and microbiology applications that require controlled containment environments. Class II cabinets remain the primary product category because they provide personnel, product, and environmental protection and are widely used across research, pharmaceutical, and clinical laboratory settings. Class II to register the highest CAGR in the biological safety cabinet market from 2026 to 2031 Based on type, the Class II segment is likely to register the highest CAGR during the forecast period. The segment is primarily driven by its ability to provide personnel, product, and environmental protection, making Class II cabinets widely applicable across pharmaceutical, biopharmaceutical, clinical, academic, and microbiology laboratories. Class II BSCs are designed for work involving Biosafety Levels 1, 2, and 3 and support applications such as cell culture and microbiological research. The expansion of pharmaceutical and biopharmaceutical research, clinical diagnostics, infectious disease studies, and academic laboratory infrastructure, coupled with replacement of aging equipment and increasing emphasis on certified containment systems, is expected to sustain demand for Class II biological safety cabinets. NSF/ANSI 49 specifically establishes design, performance, and certification requirements for Class II biosafety cabinetry. Pharma & biopharma organizations captured the largest share of the biological safety cabinet market in 2025 Based on end user, pharma & biopharma organizations accounted for the largest market share in 2025, supported by extensive use of biological safety cabinets in drug discovery, biologics development, vaccine research, cell and gene therapy, quality control, and sterile drug preparation. These organizations require controlled containment for handling microorganisms, biological samples, and potentially hazardous materials, creating sustained demand for Class II biological safety cabinets. The expansion of biopharmaceutical research and manufacturing facilities, along with increasing investments in laboratory infrastructure, is further supporting cabinet installations. Thermo Fisher Scientific identifies pharmaceutical, biotechnology, and clinical facilities among key application settings for its Class II biological safety cabinets. Asia Pacific to register the fastest growth rate in the biological safety cabinet market between 2026 and 2031 Based on region, Asia Pacific is expected to register the fastest growth during the forecast period. Regional expansion is supported by increasing investments in pharmaceutical and biopharmaceutical manufacturing, expansion of clinical and diagnostic laboratories, and growing research activities across China, India, Japan, South Korea, and other emerging economies. The region's expanding biotechnology sector, increasing vaccine and biologics development, and development of new research and healthcare facilities are generating demand for biological safety cabinets. China and India are particularly important growth markets, supported by expanding pharmaceutical and biotechnology industries and investments in laboratory infrastructure. The market presents significant growth opportunities through the modernization of laboratory infrastructure, increasing adoption of certified containment equipment, and expansion of biopharmaceutical and clinical research capabilities. Growing emphasis on laboratory biosafety and contamination control is encouraging laboratories to replace conventional or aging equipment with advanced Class II cabinets offering improved airflow control, energy efficiency, and monitoring capabilities. Breakdown of primary participants in the biological safety cabinet market is as follows: ・By Company Type: Tier 1 (32%), Tier 2 (41%), and Tier 3 (27%) ・By Designation: C-level Executives (30%), Directors (26%), and Others (44%) ・By Region: North America (53%), Europe (21%), Asia Pacific (17%), Latin America (6%), and the Middle East & Africa (4%) Key players in the biological safety cabinet market are Thermo Fisher Scientific Inc. (US), Kewaunee Scientific Corporation (US), Labconco Corporation (US), The Baker Company, Inc. (US), Esco Lifesciences (Singapore), Air Science (US), Cruma, S.A. (Spain), Berner International GmbH (USA), LaboGene ApS (Denmark), Biolab Scientific Ltd. (Canada), LAMSYSTEMS GmbH (Germany), and FASTER S.r.l. (Italy). Research Coverage: This research report categorizes the biological safety cabinet market by type (Class I, Class II, Class III), end user (Pharma & Biopharma Organizations, Clinical Laboratories, Academic & Biomedical Research Institutes, Other End Users), and region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the biological safety cabinet market. A detailed analysis of key industry players has been conducted to provide insights into their business overview, solutions, and key strategies, such as partnerships, collaborations, expansions, agreements, product launches, and recent developments in the market. This report covers the competitive analysis of upcoming startups in the biological safety cabinet ecosystem. Reasons to Buy This Report: The report will help leaders/new entrants in this market by providing information on the closest approximations of revenue for the overall biological safety cabinet market and its subsegments. This report will help stakeholders understand the competitive landscape and gain deeper insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key drivers, restraints, opportunities, and challenges. The report provides insights into the following pointers: ・Analysis of key drivers (Rising pharmaceutical and biopharmaceutical R&D activities, Rapid growth in biologics, cell and gene therapies, increasing risk of pandemics and communicable diseases, Growing concerns over cell culture contamination, Expansion of clinical diagnostics and microbiology laboratories), restraints (Availability of alternative containment cabinets, High acquisition and installation costs) opportunities (Growth opportunities in emerging economies, Development of smart and connected biological safety cabinets) and Challenges (Stringent and evolving regulatory requirements across regions, Shortage of qualified service and maintenance personnel) influencing the biological safety cabinet market growth ・Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and product launches in the biological safety cabinet market ・Market Development: Comprehensive information about lucrative markets; the report analyzes the biological safety cabinet market across varied regions ・Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the biological safety cabinet market ・Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players like Thermo Fisher Scientific Inc. (US), Kewaunee Scientific Corporation (US), Labconco Corporation (US), and The Baker Company, Inc. (US).

ページTOPに戻る

Table of Contents

1 INTRODUCTION 24
1.1 STUDY OBJECTIVES 24
1.2 MARKET DEFINITION 24
1.3 STUDY SCOPE 25
1.3.1 MARKETS COVERED AND REGIONAL SCOPE 25
1.3.2 INCLUSIONS AND EXCLUSIONS 25
1.3.3 YEARS CONSIDERED 26
1.3.4 CURRENCY CONSIDERED 26
1.4 STAKEHOLDERS 26
1.5 SUMMARY OF CHANGES 27
2 EXECUTIVE SUMMARY 28
2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS 28
2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS 29
2.3 DISRUPTIVE TRENDS SHAPING MARKET 30
2.4 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS 31
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 32
3 PREMIUM INSIGHTS 33
3.1 BIOLOGICAL SAFETY CABINET MARKET OVERVIEW 33
3.2 BIOLOGICAL SAFETY CABINET MARKET, BY TYPE, 2026 VS. 2031 33
3.3 BIOLOGICAL SAFETY CABINET MARKET, BY END USER, 2026 VS. 2031 34
3.4 BIOLOGICAL SAFETY CABINET MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 34
4 MARKET OVERVIEW 35
4.1 INTRODUCTION 35
4.2 MARKET DYNAMICS 35
4.2.1 DRIVERS 36
4.2.1.1 Growing biological development and biopharmaceutical activity 36
4.2.1.2 Increasing investments in laboratory infrastructure 36
4.2.1.3 Rising emphasis on laboratory biosafety and contamination control 37
4.2.1.4 Persistent burden of infectious diseases and pathogenic agents 37
4.2.2 RESTRAINTS 38
4.2.2.1 High installation, certification, and maintenance requirements 38
4.2.2.2 High cost of biological safety cabinets 38
4.2.3 OPPORTUNITIES 39
4.2.3.1 Growth opportunities in emerging markets 39
4.2.3.2 Technological advancements in biological safety cabinets 39
4.2.4 CHALLENGES 40
4.2.4.1 Shortage of skilled personnel for BSC certification and maintenance 40
4.3 UNMET NEEDS AND WHITE SPACES 40
4.3.1 UNMET NEEDS IN BIOLOGICAL SAFETY CABINET MARKET 40
4.3.2 WHITE SPACE OPPORTUNITIES 41
4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES 42
4.4.1 INTERCONNECTED MARKETS 42
4.4.2 CROSS-SECTOR OPPORTUNITIES 43
4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS 44
4.5.1 KEY MOVES AND STRATEGIC FOCUS 44
5 INDUSTRY TRENDS 45
5.1 PORTER’S FIVE FORCES ANALYSIS 45
5.1.1 THREAT OF NEW ENTRANTS 46
5.1.2 THREAT OF SUBSTITUTES 46
5.1.3 BARGAINING POWER OF BUYERS 46
5.1.4 BARGAINING POWER OF SUPPLIERS 46
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 46
5.2 MACROECONOMIC INDICATORS 47
5.2.1 INTRODUCTION 47
5.2.2 GDP TRENDS AND FORECAST 47
5.3 SUPPLY CHAIN ANALYSIS 50
5.4 VALUE CHAIN ANALYSIS 51
5.5 ECOSYSTEM ANALYSIS 52
5.5.1 BIOLOGICAL SAFETY CABINET MARKET: ROLE OF COMPANIES IN ECOSYSTEM 52
5.6 PRICING ANALYSIS 53
5.6.1 AVERAGE SELLING PRICE, BY KEY PLAYER, 2024–2026 53
5.6.2 AVERAGE SELLING PRICE, BY REGION, 2024–2026 54
5.7 TRADE ANALYSIS 55
5.7.1 IMPORT SCENARIO (HS CODE 8414.70) 55
5.7.2 EXPORT SCENARIO (HS CODE 8414.70) 55
5.8 KEY CONFERENCES & EVENTS, 2026–2027 56
5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 57
5.10 INVESTMENT & FUNDING SCENARIO 57
5.11 IMPACT OF 2025 US TARIFFS—BIOLOGICAL SAFETY CABINET MARKET 58
5.11.1 INTRODUCTION 58
5.11.2 KEY TARIFF RATES 58
5.11.3 PRICE IMPACT ANALYSIS 59
5.11.4 IMPACT ON REGIONS 59
5.11.4.1 North America 59
5.11.4.2 Europe 60
5.11.4.3 Asia Pacific 60
5.11.5 IMPACT ON END-USE INDUSTRIES 60
5.11.5.1 Pharmaceutical & biopharmaceutical companies 60
5.11.5.2 Clinical laboratories 60
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 61
6.1 KEY EMERGING TECHNOLOGIES 61
6.1.1 HEPA FILTRATION 61
6.1.2 AIRFLOW & CONTAINMENT CONTROL 61
6.2 COMPLEMENTARY TECHNOLOGIES 61
6.2.1 DECONTAMINATION TECHNOLOGY 61
6.3 ADJACENT TECHNOLOGIES 62
6.3.1 LABORATORY ENVIRONMENTAL MONITORING SYSTEMS 62
6.4 TECHNOLOGY/PRODUCT ROADMAP 62
6.5 PATENT ANALYSIS 64
6.5.1 LIST OF MAJOR PATENTS 65
6.6 FUTURE APPLICATIONS 65
6.7 IMPACT OF AI/GENERATIVE AI ON BIOLOGICAL SAFETY CABINET MARKET 67
6.7.1 INTRODUCTION 67
6.7.2 TOP USE CASES AND MARKET POTENTIAL 67
6.7.3 KEY COMPANIES IMPLEMENTING AI 68
6.7.4 FUTURE OF AI/GEN AI 68
7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES 69
7.1 REGIONAL REGULATIONS AND COMPLIANCE 69
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 69
7.2 SUSTAINABILITY INITIATIVES 71
7.2.1 ENVIRONMENTAL IMPACT AND ECO-FRIENDLY INITIATIVES IN BIOLOGICAL SAFETY CABINET 71
7.2.1.1 Eco-friendly Initiatives 71
7.3 IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY INITIATIVES 72
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 73
8.1 DECISION-MAKING PROCESS 73
8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA 73
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 73
8.2.2 BUYING CRITERIA 74
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 75
8.4 UNMET NEEDS IN VARIOUS END-USE INDUSTRIES 77
8.5 MARKET PROFITABILITY 78
8.5.1 REVENUE POTENTIAL 78
8.5.2 COST DYNAMICS 78
8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS 79
9 BIOLOGICAL SAFETY CABINET MARKET, BY TYPE 80
9.1 INTRODUCTION 81
9.2 CLASS I 81
9.2.1 BASIC CONTAINMENT REQUIREMENTS SUSTAIN CLASS I CABINET DEMAND 81
9.3 CLASS II 83
9.3.1 CLASS II TYPE A 85
9.3.1.1 Class II Type A1 87
9.3.1.1.1 Established laboratory installations maintain Type A1 demand 87
9.3.1.2 Class II Type A2 89
9.3.1.2.1 Broad biological workflows drive Type A2 demand 89
9.3.2 CLASS II TYPE B 90
9.3.2.1 Class II Type B1 92
9.3.2.1.1 Specialized chemical-biological applications support Type B1 demand 92
9.3.2.2 Class II Type B2 94
9.3.2.2.1 Total-exhaust requirements support specialized Type B2 demand 94
9.3.3 CLASS II TYPE C1 96
9.3.3.1 Flexible exhaust configurations create a differentiated Type C1 niche 96
9.4 CLASS III 97
9.4.1 MAXIMUM-CONTAINMENT REQUIREMENTS SUPPORT CLASS III CABINET DEMAND 97
10 BIOLOGICAL SAFETY CABINET MARKET, BY END USER 100
10.1 INTRODUCTION 101
10.2 PHARMA & BIOPHARMA ORGANIZATIONS 101
10.2.1 RISING BIOLOGICS DEVELOPMENT AND R&D INVESTMENT TO DRIVE HIGH-END BSC ADOPTION 101
10.3 CLINICAL LABORATORIES 103
10.3.1 RISING DISEASE BURDEN AND DIAGNOSTIC TESTING VOLUMES TO SUPPORT MARKET GROWTH 103
10.4 ACADEMIC & BIOMEDICAL RESEARCH INSTITUTES 105
10.4.1 SUSTAINED RESEARCH FUNDING TO SHAPE MARKET GROWTH 105
10.5 OTHER END USERS 107
11 BIOLOGICAL SAFETY CABINET MARKET, BY REGION 109
11.1 INTRODUCTION 110
11.2 NORTH AMERICA 111
11.2.1 US 114
11.2.1.1 Growth in biosimilars market to boost preclinical research 114
11.2.2 CANADA 116
11.2.2.1 Government support for R&D to support market growth 116
11.3 EUROPE 119
11.3.1 GERMANY 121
11.3.1.1 Increased pharmaceutical R&D and biomanufacturing investments to drive market growth 121
11.3.2 UK 123
11.3.2.1 Expanding biopharmaceutical R&D to support market growth 123
11.3.3 FRANCE 125
11.3.3.1 Expansion of biopharmaceutical manufacturing to support market growth 125
11.3.4 ITALY 127
11.3.4.1 Expansion of biomedical research to support market growth 127
11.3.5 SPAIN 129
11.3.5.1 Expansion of biomedical research to support market growth 129
11.3.6 REST OF EUROPE 131
11.4 ASIA PACIFIC 133
11.4.1 CHINA 137
11.4.1.1 Government support for innovative drug development to support market growth 137
11.4.2 JAPAN 139
11.4.2.1 Strong academic–industry collaboration to support market growth 139
11.4.3 INDIA 141
11.4.3.1 Expansion of biotechnology research and biomanufacturing to support market growth 141
11.4.4 REST OF ASIA PACIFIC 143
11.5 LATIN AMERICA 145
11.5.1 EXPANSION OF PHARMACEUTICAL R&D AND CLINICAL RESEARCH TO SUPPORT MARKET GROWTH 145
11.6 MIDDLE EAST & AFRICA 147
11.6.1 INCREASING CLINICAL RESEARCH AND BIOTECHNOLOGY ACTIVITIES TO DRIVE MARKET GROWTH 147
12 COMPETITIVE LANDSCAPE 150
12.1 INTRODUCTION 150
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 150
12.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN BIOLOGICAL SAFETY CABINET MARKET 151
12.3 REVENUE ANALYSIS, 2023–2025 152
12.4 MARKET SHARE ANALYSIS, 2025 152
12.4.1 GLOBAL MARKET SHARE ANALYSIS, 2025 153
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 154
12.5.1 STARS 154
12.5.2 EMERGING LEADERS 154
12.5.3 PERVASIVE PLAYERS 154
12.5.4 PARTICIPANTS 155
12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 156
12.5.5.1 Company footprint 156
12.5.5.2 Region footprint 156
12.5.5.3 Type footprint 157
12.5.5.4 End-user footprint 157
12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 158
12.6.1 PROGRESSIVE COMPANIES 158
12.6.2 RESPONSIVE COMPANIES 158
12.6.3 DYNAMIC COMPANIES 158
12.6.4 STARTING BLOCKS 158
12.6.5 COMPANY FOOTPRINT: STARTUPS/SMES, 2025 160
12.6.5.1 Detailed list of key startups/SMEs 160
12.7 COMPANY VALUATION & FINANCIAL METRICS 162
12.7.1 FINANCIAL METRICS 162
12.7.2 COMPANY VALUATION 162
12.8 BRAND/PRODUCT COMPARISON 163
12.9 COMPETITIVE SCENARIO 164
12.9.1 PRODUCT/SERVICE LAUNCHES & APPROVALS 164
12.9.2 DEALS 165
12.9.3 EXPANSIONS 165
13 COMPANY PROFILES 166
13.1 KEY PLAYERS 166
13.1.1 THERMO FISHER SCIENTIFIC INC. 166
13.1.1.1 Business overview 166
13.1.1.2 Products offered 167
13.1.1.3 MnM view 168
13.1.1.3.1 Right to win 168
13.1.1.3.2 Strategic choices 168
13.1.1.3.3 Weaknesses & competitive threats 168
13.1.2 KEWAUNEE SCIENTIFIC CORPORATION 169
13.1.2.1 Business overview 169
13.1.2.2 Products offered 170
13.1.2.3 Recent developments 171
13.1.2.3.1 Deals 171
13.1.2.4 MnM view 171
13.1.2.4.1 Right to win 171
13.1.2.4.2 Strategic choices 171
13.1.2.4.3 Weaknesses & competitive threats 171
13.1.3 ESCO LIFESCIENCES GROUP 172
13.1.3.1 Business overview 172
13.1.3.2 Products offered 172
13.1.3.3 Recent developments 174
13.1.3.3.1 Product launches & approvals 174
13.1.3.3.2 Deals 174
13.1.3.3.3 Expansions 175
13.1.3.4 MnM view 175
13.1.3.4.1 Right to win 175
13.1.3.4.2 Strategic choices 175
13.1.3.4.3 Weaknesses & competitive threats 175
13.1.4 LABCONCO CORPORATION 176
13.1.4.1 Business overview 176
13.1.4.2 Products offered 176
13.1.4.3 Recent developments 177
13.1.4.3.1 Product launches & approvals 177
13.1.4.4 MnM view 178
13.1.4.4.1 Right to win 178
13.1.4.4.2 Strategic choices 178
13.1.4.4.3 Weaknesses & competitive threats 178
13.1.5 THE BAKER COMPANY, INC. 179
13.1.5.1 Business overview 179
13.1.5.2 Products offered 179
13.1.5.3 Recent developments 180
13.1.5.3.1 Product launches & approvals 180
13.1.5.4 MnM view 180
13.1.5.4.1 Right to win 180
13.1.5.4.2 Strategic choices 180
13.1.5.4.3 Weaknesses & competitive threats 180
13.1.6 GERMFREE LABORATORIES, INC. 181
13.1.6.1 Business overview 181
13.1.6.2 Products offered 181
13.1.7 CRUMA 183
13.1.7.1 Business overview 183
13.1.7.2 Products offered 183
13.1.8 AIR SCIENCE USA LLC 185
13.1.8.1 Business overview 185
13.1.8.2 Products offered 185
13.1.9 BERNER INTERNATIONAL GMBH 186
13.1.9.1 Business overview 186
13.1.9.2 Products offered 186
13.1.10 LABOGENE 188
13.1.10.1 Business overview 188
13.1.10.2 Products offered 188
13.1.11 BIOLAB SCIENTIFIC LTD. 189
13.1.11.1 Business overview 189
13.1.11.2 Products offered 189
13.1.12 LAMSYSTEMS CC 191
13.1.12.1 Business overview 191
13.1.12.2 Products offered 191
13.2 OTHER PLAYERS 193
13.2.1 FASTER S.R.L. 193
13.2.2 BIOBASE GROUP 194
13.2.3 THERMOLAB SCIENTIFIC EQUIPMENTS PVT. LTD. 194
13.2.4 LABMATE SCIENTIFIC LLC 195
13.2.5 TOPAIR SYSTEMS INC. 195
13.2.6 ZHEJIANG FUXIA MEDICAL TECHNOLOGY CO., LTD. 196
13.2.7 BIONICS SCIENTIFIC 196
13.2.8 SCITEK GLOBAL CO., LTD. 197
13.2.9 HEAL FORCE BIO-MEDITECH HOLDINGS LIMITED 198
13.2.10 SHANGHAI BOXUN MEDICAL BIOLOGICAL INSTRUMENT CORP. 198
13.2.11 HAIER BIOMEDICAL 199
13.2.12 HMC EUROPE GMBH 199
13.2.13 NORDIC LABTECH AB 200
14 RESEARCH METHODOLOGY 201
14.1 RESEARCH DATA 201
14.2 RESEARCH APPROACH 201
14.2.1 SECONDARY DATA 202
14.2.1.1 Key data from secondary sources 202
14.2.2 PRIMARY DATA 203
14.2.2.1 List of primary sources 203
14.2.2.2 Key data from primary sources 204
14.2.2.3 Key industry insights 205
14.2.2.4 Breakdown of primary interviews 205
14.3 MARKET SIZE ESTIMATION 206
14.3.1 TOTAL MARKET SIZE: BIOLOGICAL SAFETY CABINET MARKET 206
14.3.2 BOTTOM-UP APPROACH 206
14.3.2.1 Approach 1: Company revenue estimation approach 206
14.3.2.2 Approach 2: Presentations of companies and primary interviews 207
14.3.2.3 Growth forecast 207
14.3.2.4 CAGR projections 207
14.3.3 TOP-DOWN APPROACH 208
14.4 DATA TRIANGULATION 209
14.5 RESEARCH ASSUMPTIONS 209
14.5.1 STUDY-RELATED ASSUMPTIONS 209
14.6 STUDY ASSUMPTIONS 210
14.6.1 PARAMETRIC ASSUMPTIONS 210
14.6.2 GROWTH RATE ASSUMPTIONS 211
14.7 RESEARCH LIMITATIONS 211
14.8 RISK ASSESSMENT 211
15 APPENDIX 212
15.1 DISCUSSION GUIDE 212
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 215
15.3 CUSTOMIZATION OPTIONS 217
15.4 RELATED REPORTS 217
15.5 AUTHOR DETAILS 218

ページTOPに戻る

List of Tables/Graphs

FIGURE 1 BIOLOGICAL SAFETY CABINET MARKET SEGMENTATION 25.
FIGURE 2 KEY INSIGHTS AND MARKET HIGHLIGHTS 28.
FIGURE 3 GLOBAL BIOLOGICAL SAFETY CABINET MARKET, 2024–2031 29.
FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN BIOLOGICAL SAFETY CABINET MARKET, 2023–2025 29.
FIGURE 5 DISRUPTIVE TRENDS IMPACTING GROWTH OF BIOLOGICAL SAFETY CABINET MARKET 30.
FIGURE 6 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS IN BIOLOGICAL SAFETY CABINET MARKET, 2026–2031 31.
FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 32.
FIGURE 8 INCREASING INVESTMENTS IN LABORATORY INFRASTRUCTURE AND BIOSAFETY TO DRIVE MARKET 33.
FIGURE 9 CLASS II SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 33.
FIGURE 10 PHARMA & BIOPHARMA ORGANIZATIONS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 34.
FIGURE 11 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 34.
FIGURE 12 BIOLOGICAL SAFETY CABINET MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 35.
FIGURE 13 BIOLOGICAL SAFETY CABINET MARKET: PORTER’S FIVE FORCES ANALYSIS 45.
FIGURE 14 BIOLOGICAL SAFETY CABINET MARKET: SUPPLY CHAIN ANALYSIS 50.
FIGURE 15 BIOLOGICAL SAFETY CABINET MARKET: VALUE CHAIN ANALYSIS 51.
FIGURE 16 BIOLOGICAL SAFETY CABINET MARKET: ECOSYSTEM ANALYSIS 52.
FIGURE 17 BIOLOGICAL SAFETY CABINET MARKET: TRENDS AND DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 57.
FIGURE 18 NUMBER OF DEALS & FUNDING ACTIVITIES IN BIOLOGICAL SAFETY CABINET MARKET 58.
FIGURE 19 PATENT ANALYSIS FOR BIOLOGICAL SAFETY CABINETS, JANUARY 2016–DECEMBER 2025 64.
FIGURE 20 MARKET POTENTIAL OF AI IN BIOLOGICAL SAFETY CABINET MARKET 67.
FIGURE 21 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF BIOLOGICAL SAFETY CABINET PRODUCTS, BY TYPE 73.
FIGURE 22 KEY BUYING CRITERIA FOR BIOLOGICAL SAFETY CABINETS, BY TYPE 74.
FIGURE 23 NORTH AMERICA: BIOLOGICAL SAFETY CABINET MARKET SNAPSHOT 111.
FIGURE 24 ASIA PACIFIC: BIOLOGICAL SAFETY CABINET MARKET SNAPSHOT 134.
FIGURE 25 REVENUE ANALYSIS OF KEY PLAYERS IN BIOLOGICAL SAFETY CABINET MARKET, 2023–2025 (USD MILLION) 152.
FIGURE 26 BIOLOGICAL SAFETY CABINET MARKET SHARE ANALYSIS, 2025 (GLOBAL) 153.
FIGURE 27 BIOLOGICAL SAFETY CABINET MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 155.
FIGURE 28 BIOLOGICAL SAFETY CABINET MARKET: COMPANY FOOTPRINT 156.
FIGURE 29 BIOLOGICAL SAFETY CABINET MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 159.
FIGURE 30 EV/EBITDA OF KEY VENDORS 162.
FIGURE 31 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 162.
FIGURE 32 BIOLOGICAL SAFETY CABINET MARKET: PRODUCT COMPARISON FOR BIOLOGICAL SAFETY CABINET 163.
FIGURE 33 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025) 167.
FIGURE 34 KEWAUNEE SCIENTIFIC CORPORATION: COMPANY SNAPSHOT (2025) 170.
FIGURE 35 BIOLOGICAL SAFETY CABINET MARKET: RESEARCH DESIGN METHODOLOGY 201.
FIGURE 36 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 205.
FIGURE 37 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH 206.
FIGURE 38 BIOLOGICAL SAFETY CABINET MARKET: TOP-DOWN APPROACH 208.
FIGURE 39 DATA TRIANGULATION METHODOLOGY 209.
TABLE 1 BIOLOGICAL SAFETY CABINET MARKET: PORTER’S FIVE FORCES ANALYSIS 45.
TABLE 2 GDP PERCENTAGE CHANGE (%), BY KEY COUNTRY, 2023–2030 47.
TABLE 3 NORTH AMERICA: MACROECONOMIC INDICATORS 48.
TABLE 4 EUROPE: MACROECONOMIC INDICATORS 49.
TABLE 5 ASIA PACIFIC: MACROECONOMIC INDICATORS 49.
TABLE 6 LATIN AMERICA: MACROECONOMIC INDICATORS 49.
TABLE 7 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS 49.
TABLE 8 AVERAGE SELLING PRICE OF BIOLOGICAL SAFETY CABINET PRODUCTS, BY KEY PLAYER, 2024–2026 (USD) 53.
TABLE 9 AVERAGE SELLING PRICE OF BIOLOGICAL SAFETY CABINET PRODUCTS, BY REGION, 2024–2026 (USD) 54.
TABLE 10 IMPORT DATA FOR HS CODE 8414.70-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD MILLION) 55.
TABLE 11 EXPORT DATA FOR HS CODE 8414.70-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD MILLION) 55.
TABLE 12 BIOLOGICAL SAFETY CABINET MARKET: MAJOR CONFERENCES & EVENTS, 2026–2027 56.
TABLE 13 US-ADJUSTED RECIPROCAL TARIFF RATES 58.
TABLE 14 KEY PATENTS IN BIOLOGICAL SAFETY CABINET MARKET, 2022–2026 65.
TABLE 15 KEY COMPANIES IMPLEMENTING AI IN BIOLOGICAL SAFETY CABINET MARKET 68.
TABLE 16 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 69.
TABLE 17 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 69.
TABLE 18 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 70.
TABLE 19 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 70.
TABLE 20 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 71.
TABLE 21 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF BIOLOGICAL SAFETY CABINET PRODUCTS, BY TYPE (%) 74.
TABLE 22 KEY BUYING CRITERIA FOR BIOLOGICAL SAFETY CABINETS, BY TYPE 74.
TABLE 23 ADOPTION BARRIERS & INTERNAL CHALLENGES 75.
TABLE 24 BIOLOGICAL SAFETY CABINET MARKET: UNMET NEEDS IN VARIOUS END-USE INDUSTRIES 77.
TABLE 25 BIOLOGICAL SAFETY CABINET MARKET, BY TYPE, 2024–2031 (USD MILLION) 81.
TABLE 26 CLASS I BIOLOGICAL SAFETY CABINETS MARKET, BY REGION, 2024–2031 (USD MILLION) 82.
TABLE 27 NORTH AMERICA: CLASS I BIOLOGICAL SAFETY CABINETS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 82.
TABLE 28 EUROPE: CLASS I BIOLOGICAL SAFETY CABINETS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 82.
TABLE 29 ASIA PACIFIC: CLASS I BIOLOGICAL SAFETY CABINETS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 83.
TABLE 30 CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024–2031 (USD MILLION) 83.
TABLE 31 CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY REGION, 2024–2031 (USD MILLION) 84.
TABLE 32 NORTH AMERICA: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 84.
TABLE 33 EUROPE: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 84.
TABLE 34 ASIA PACIFIC: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 85.
TABLE 35 CLASS II TYPE A BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024–2031 (USD MILLION) 85.
TABLE 36 CLASS II TYPE A BIOLOGICAL SAFETY CABINETS MARKET, BY REGION, 2024–2031 (USD MILLION) 86.
TABLE 37 NORTH AMERICA: CLASS II TYPE A BIOLOGICAL SAFETY CABINETS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 86.
TABLE 38 EUROPE: CLASS II TYPE A BIOLOGICAL SAFETY CABINETS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 86.
TABLE 39 ASIA PACIFIC: CLASS II TYPE A BIOLOGICAL SAFETY CABINETS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 87.
TABLE 40 CLASS II TYPE A1 BIOLOGICAL SAFETY CABINETS MARKET, BY REGION, 2024–2031 (USD MILLION) 87.
TABLE 41 NORTH AMERICA: CLASS II TYPE A1 BIOLOGICAL SAFETY CABINETS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 88.
TABLE 42 EUROPE: CLASS II TYPE A1 BIOLOGICAL SAFETY CABINETS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 88.
TABLE 43 ASIA PACIFIC: CLASS II TYPE A1 BIOLOGICAL SAFETY CABINETS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 88.
TABLE 44 CLASS II TYPE A2 BIOLOGICAL SAFETY CABINETS MARKET, BY REGION, 2024–2031 (USD MILLION) 89.
TABLE 45 NORTH AMERICA: CLASS II TYPE A2 BIOLOGICAL SAFETY CABINETS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 89.
TABLE 46 EUROPE: CLASS II TYPE A2 BIOLOGICAL SAFETY CABINETS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 90.
TABLE 47 ASIA PACIFIC: CLASS II TYPE A2 BIOLOGICAL SAFETY CABINETS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 90.
TABLE 48 CLASS II TYPE B BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024–2031 (USD MILLION) 91.
TABLE 49 CLASS II TYPE B BIOLOGICAL SAFETY CABINETS MARKET, BY REGION, 2024–2031 (USD MILLION) 91.
TABLE 50 NORTH AMERICA: CLASS II TYPE B BIOLOGICAL SAFETY CABINETS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 91.
TABLE 51 EUROPE: CLASS II TYPE B BIOLOGICAL SAFETY CABINETS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 92.
TABLE 52 ASIA PACIFIC: CLASS II TYPE B BIOLOGICAL SAFETY CABINETS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 92.
TABLE 53 CLASS II TYPE B1 BIOLOGICAL SAFETY CABINETS MARKET, BY REGION, 2024–2031 (USD MILLION) 93.
TABLE 54 NORTH AMERICA: CLASS II TYPE B1 BIOLOGICAL SAFETY CABINETS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 93.
TABLE 55 EUROPE: CLASS II TYPE B1 BIOLOGICAL SAFETY CABINETS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 93.
TABLE 56 ASIA PACIFIC: CLASS II TYPE B1 BIOLOGICAL SAFETY CABINETS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 94.
TABLE 57 CLASS II TYPE B2 BIOLOGICAL SAFETY CABINETS MARKET, BY REGION, 2024–2031 (USD MILLION) 94.
TABLE 58 NORTH AMERICA: CLASS II TYPE B2 BIOLOGICAL SAFETY CABINETS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 95.
TABLE 59 EUROPE: CLASS II TYPE B2 BIOLOGICAL SAFETY CABINETS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 95.
TABLE 60 ASIA PACIFIC: CLASS II TYPE B2 BIOLOGICAL SAFETY CABINETS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 95.
TABLE 61 CLASS II TYPE C1 BIOLOGICAL SAFETY CABINETS MARKET, BY REGION, 2024–2031 (USD MILLION) 96.
TABLE 62 NORTH AMERICA: CLASS II TYPE C1 BIOLOGICAL SAFETY CABINETS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 96.
TABLE 63 EUROPE: CLASS II TYPE C1 BIOLOGICAL SAFETY CABINETS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 97.
TABLE 64 CLASS III BIOLOGICAL SAFETY CABINETS MARKET, BY REGION, 2024–2031 (USD MILLION) 98.
TABLE 65 NORTH AMERICA: CLASS III BIOLOGICAL SAFETY CABINETS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 98.
TABLE 66 EUROPE: CLASS III BIOLOGICAL SAFETY CABINETS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 98.
TABLE 67 ASIA PACIFIC: CLASS III BIOLOGICAL SAFETY CABINETS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 99.
TABLE 68 BIOLOGICAL SAFETY CABINET MARKET, BY END USER, 2024–2031 (USD MILLION) 101.
TABLE 69 BIOLOGICAL SAFETY CABINET MARKET FOR PHARMA & BIOPHARMA ORGANIZATIONS, BY REGION, 2024–2031 (USD MILLION) 102.
TABLE 70 NORTH AMERICA: BIOLOGICAL SAFETY CABINET MARKET FOR PHARMA & BIOPHARMA ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 102.
TABLE 71 EUROPE: BIOLOGICAL SAFETY CABINET MARKET FOR PHARMA & BIOPHARMA ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 102.
TABLE 72 ASIA PACIFIC: BIOLOGICAL SAFETY CABINET MARKET FOR PHARMA & BIOPHARMA ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 103.
TABLE 73 BIOLOGICAL SAFETY CABINET MARKET FOR CLINICAL LABORATORIES, BY REGION, 2024–2031 (USD MILLION) 104.
TABLE 74 NORTH AMERICA: BIOLOGICAL SAFETY CABINET MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 104.
TABLE 75 EUROPE: BIOLOGICAL SAFETY CABINET MARKET CLINICAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 104.
TABLE 76 ASIA PACIFIC: BIOLOGICAL SAFETY CABINET MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 105.
TABLE 77 BIOLOGICAL SAFETY CABINET MARKET FOR ACADEMIC & BIOMEDICAL RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION) 105.
TABLE 78 NORTH AMERICA: BIOLOGICAL SAFETY CABINET MARKET FOR ACADEMIC & BIOMEDICAL RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 106.
TABLE 79 EUROPE: BIOLOGICAL SAFETY CABINET MARKET FOR ACADEMIC & BIOMEDICAL RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 106.
TABLE 80 ASIA PACIFIC: BIOLOGICAL SAFETY CABINET MARKET FOR ACADEMIC & BIOMEDICAL RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 106.
TABLE 81 BIOLOGICAL SAFETY CABINET MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION) 107.
TABLE 82 NORTH AMERICA: BIOLOGICAL SAFETY CABINET MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 107.
TABLE 83 EUROPE: BIOLOGICAL SAFETY CABINET MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 108.
TABLE 84 ASIA PACIFIC: BIOLOGICAL SAFETY CABINET MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 108.
TABLE 85 BIOLOGICAL SAFETY CABINET MARKET, BY REGION, 2024–2031 (USD MILLION) 110.
TABLE 86 NORTH AMERICA: MACROECONOMIC INDICATORS 111.
TABLE 87 NORTH AMERICA: BIOLOGICAL SAFETY CABINET MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 112.
TABLE 88 NORTH AMERICA: BIOLOGICAL SAFETY CABINET MARKET, BY TYPE, 2024–2031 (USD MILLION) 112.
TABLE 89 NORTH AMERICA: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024–2031 (USD MILLION) 112.
TABLE 90 NORTH AMERICA: CLASS II TYPE A BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024–2031 (USD MILLION) 113.
TABLE 91 NORTH AMERICA: CLASS II TYPE B BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024–2031 (USD MILLION) 113.
TABLE 92 NORTH AMERICA: BIOLOGICAL SAFETY CABINET MARKET, BY END USER, 2024–2031 (USD MILLION) 113.
TABLE 93 US BIOLOGICAL SAFETY CABINET MARKET VOLUME, 2024–2031 (UNITS) 115.
TABLE 94 US: BIOLOGICAL SAFETY CABINET MARKET, BY TYPE, 2024–2031 (USD MILLION) 115.
TABLE 95 US: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024–2031 (USD MILLION) 115.
TABLE 96 US: CLASS II TYPE A BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024–2031 (USD MILLION) 115.
TABLE 97 US: CLASS II TYPE B BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024–2031 (USD MILLION) 116.
TABLE 98 US: BIOLOGICAL SAFETY CABINET MARKET, BY END USER, 2024–2031 (USD MILLION) 116.
TABLE 99 CANADA: BIOLOGICAL SAFETY CABINET MARKET, BY TYPE, 2024–2031 (USD MILLION) 117.
TABLE 100 CANADA: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024–2031 (USD MILLION) 117.
TABLE 101 CANADA: CLASS II TYPE A BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024–2031 (USD MILLION) 117.
TABLE 102 CANADA: CLASS II TYPE B BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024–2031 (USD MILLION) 118.
TABLE 103 CANADA: BIOLOGICAL SAFETY CABINET MARKET, BY END USER, 2024–2031 (USD MILLION) 118.
TABLE 104 EUROPE: MACROECONOMIC INDICATORS 119.
TABLE 105 EUROPE: BIOLOGICAL SAFETY CABINET MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 119.
TABLE 106 EUROPE: BIOLOGICAL SAFETY CABINET MARKET, BY TYPE, 2024–2031 (USD MILLION) 120.
TABLE 107 EUROPE: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024–2031 (USD MILLION) 120.
TABLE 108 EUROPE: CLASS II TYPE A BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024–2031 (USD MILLION) 120.
TABLE 109 EUROPE: CLASS II TYPE B BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024–2031 (USD MILLION) 121.
TABLE 110 EUROPE: BIOLOGICAL SAFETY CABINET MARKET, BY END USER, 2024–2031 (USD MILLION) 121.
TABLE 111 GERMANY: BIOLOGICAL SAFETY CABINET MARKET, BY TYPE, 2024–2031 (USD MILLION) 122.
TABLE 112 GERMANY: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024–2031 (USD MILLION) 122.
TABLE 113 GERMANY: CLASS II TYPE A BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024–2031 (USD MILLION) 122.
TABLE 114 GERMANY: CLASS II TYPE B BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024–2031 (USD MILLION) 123.
TABLE 115 GERMANY: BIOLOGICAL SAFETY CABINET MARKET, BY END USER, 2024–2031 (USD MILLION) 123.
TABLE 116 UK: BIOLOGICAL SAFETY CABINET MARKET, BY TYPE, 2024–2031 (USD MILLION) 124.
TABLE 117 UK: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024–2031 (USD MILLION) 124.
TABLE 118 UK: CLASS II TYPE A BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024–2031 (USD MILLION) 124.
TABLE 119 UK: CLASS II TYPE B BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024–2031 (USD MILLION) 125.
TABLE 120 UK: BIOLOGICAL SAFETY CABINET MARKET, BY END USER, 2024–2031 (USD MILLION) 125.
TABLE 121 FRANCE: BIOLOGICAL SAFETY CABINET MARKET, BY TYPE, 2024–2031 (USD MILLION) 126.
TABLE 122 FRANCE: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024–2031 (USD MILLION) 126.
TABLE 123 FRANCE: CLASS II TYPE A BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024–2031 (USD MILLION) 126.
TABLE 124 FRANCE: CLASS II TYPE B BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024–2031 (USD MILLION) 127.
TABLE 125 FRANCE: BIOLOGICAL SAFETY CABINET MARKET, BY END USER, 2024–2031 (USD MILLION) 127.
TABLE 126 ITALY: BIOLOGICAL SAFETY CABINET MARKET, BY TYPE, 2024–2031 (USD MILLION) 128.
TABLE 127 ITALY: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024–2031 (USD MILLION) 128.
TABLE 128 ITALY: CLASS II TYPE A BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024–2031 (USD MILLION) 128.
TABLE 129 ITALY: CLASS II TYPE B BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024–2031 (USD MILLION) 129.
TABLE 130 ITALY: BIOLOGICAL SAFETY CABINET MARKET, BY END USER, 2024–2031 (USD MILLION) 129.
TABLE 131 SPAIN: BIOLOGICAL SAFETY CABINET MARKET, BY TYPE, 2024–2031 (USD MILLION) 130.
TABLE 132 SPAIN: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024–2031 (USD MILLION) 130.
TABLE 133 SPAIN: CLASS II TYPE A BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024–2031 (USD MILLION) 130.
TABLE 134 SPAIN: CLASS II TYPE B BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024–2031 (USD MILLION) 131.
TABLE 135 SPAIN: BIOLOGICAL SAFETY CABINET MARKET, BY END USER, 2024–2031 (USD MILLION) 131.
TABLE 136 REST OF EUROPE: BIOLOGICAL SAFETY CABINET MARKET, BY TYPE, 2024–2031 (USD MILLION) 132.
TABLE 137 REST OF EUROPE: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024–2031 (USD MILLION) 132.
TABLE 138 REST OF EUROPE: CLASS II TYPE A BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024–2031 (USD MILLION) 132.
TABLE 139 REST OF EUROPE: CLASS II TYPE B BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024–2031 (USD MILLION) 133.
TABLE 140 REST OF EUROPE: BIOLOGICAL SAFETY CABINET MARKET, BY END USER, 2024–2031 (USD MILLION) 133.
TABLE 141 ASIA PACIFIC: MACROECONOMIC INDICATORS 134.
TABLE 142 ASIA PACIFIC: BIOLOGICAL SAFETY CABINET MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 135.
TABLE 143 ASIA PACIFIC: BIOLOGICAL SAFETY CABINET MARKET, BY TYPE, 2024–2031 (USD MILLION) 135.
TABLE 144 ASIA PACIFIC: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024–2031 (USD MILLION) 135.
TABLE 145 ASIA PACIFIC: CLASS II TYPE A BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024–2031 (USD MILLION) 136.
TABLE 146 ASIA PACIFIC: CLASS II TYPE B BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024–2031 (USD MILLION) 136.
TABLE 147 ASIA PACIFIC: BIOLOGICAL SAFETY CABINET MARKET, BY END USER, 2024–2031 (USD MILLION) 136.
TABLE 148 CHINA: BIOLOGICAL SAFETY CABINET MARKET, BY TYPE, 2024–2031 (USD MILLION) 137.
TABLE 149 CHINA: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024–2031 (USD MILLION) 137.
TABLE 150 CHINA: CLASS II TYPE A BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024–2031 (USD MILLION) 138.
TABLE 151 CHINA: CLASS II TYPE B BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024–2031 (USD MILLION) 138.
TABLE 152 CHINA: BIOLOGICAL SAFETY CABINET MARKET, BY END USER, 2024–2031 (USD MILLION) 138.
TABLE 153 JAPAN: BIOLOGICAL SAFETY CABINET MARKET, BY TYPE, 2024–2031 (USD MILLION) 139.
TABLE 154 JAPAN: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024–2031 (USD MILLION) 139.
TABLE 155 JAPAN: CLASS II TYPE A BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024–2031 (USD MILLION) 140.
TABLE 156 JAPAN: CLASS II TYPE B BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024–2031 (USD MILLION) 140.
TABLE 157 JAPAN: BIOLOGICAL SAFETY CABINET MARKET, BY END USER, 2024–2031 (USD MILLION) 140.
TABLE 158 INDIA: BIOLOGICAL SAFETY CABINET MARKET, BY TYPE, 2024–2031 (USD MILLION) 141.
TABLE 159 INDIA: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024–2031 (USD MILLION) 141.
TABLE 160 INDIA: CLASS II TYPE A BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024–2031 (USD MILLION) 142.
TABLE 161 INDIA: CLASS II TYPE B BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024–2031 (USD MILLION) 142.
TABLE 162 INDIA: BIOLOGICAL SAFETY CABINET MARKET, BY END USER, 2024–2031 (USD MILLION) 142.
TABLE 163 REST OF ASIA PACIFIC: BIOLOGICAL SAFETY CABINET MARKET, BY TYPE, 2024–2031 (USD MILLION) 143.
TABLE 164 REST OF ASIA PACIFIC: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024–2031 (USD MILLION) 143.
TABLE 165 REST OF ASIA PACIFIC: CLASS II TYPE A BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024–2031 (USD MILLION) 144.
TABLE 166 REST OF ASIA PACIFIC: CLASS II TYPE B BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024–2031 (USD MILLION) 144.
TABLE 167 REST OF ASIA PACIFIC: BIOLOGICAL SAFETY CABINET MARKET, BY END USER, 2024–2031 (USD MILLION) 144.
TABLE 168 LATIN AMERICA: BIOLOGICAL SAFETY CABINET MARKET, BY TYPE, 2024–2031 (USD MILLION) 145.
TABLE 169 LATIN AMERICA: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024–2031 (USD MILLION) 146.
TABLE 170 LATIN AMERICA: CLASS II TYPE A BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024–2031 (USD MILLION) 146.
TABLE 171 LATIN AMERICA: CLASS II TYPE B BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024–2031 (USD MILLION) 146.
TABLE 172 LATIN AMERICA: BIOLOGICAL SAFETY CABINET MARKET, BY END USER, 2024–2031 (USD MILLION) 147.
TABLE 173 MIDDLE EAST & AFRICA: BIOLOGICAL SAFETY CABINET MARKET, BY TYPE, 2024–2031 (USD MILLION) 148.
TABLE 174 MIDDLE EAST & AFRICA: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024–2031 (USD MILLION) 148.
TABLE 175 MIDDLE EAST & AFRICA: CLASS II TYPE A BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024–2031 (USD MILLION) 148.
TABLE 176 MIDDLE EAST & AFRICA: CLASS II TYPE B BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024–2031 (USD MILLION) 149.
TABLE 177 MIDDLE EAST & AFRICA: BIOLOGICAL SAFETY CABINET MARKET, BY END USER, 2024–2031 (USD MILLION) 149.
TABLE 178 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES IN BIOLOGICAL SAFETY CABINET MARKET, JANUARY 2023–AUGUST 2026 151.
TABLE 179 BIOLOGICAL SAFETY CABINET MARKET: DEGREE OF COMPETITION 153.
TABLE 180 BIOLOGICAL SAFETY CABINET MARKET: REGION FOOTPRINT 156.
TABLE 181 BIOLOGICAL SAFETY CABINET MARKET: TYPE FOOTPRINT 157.
TABLE 182 BIOLOGICAL SAFETY CABINET MARKET: END USER FOOTPRINT 157.
TABLE 183 BIOLOGICAL SAFETY CABINET MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS 160.
TABLE 184 BIOLOGICAL SAFETY CABINET MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUP/SME PLAYERS 161.
TABLE 185 BIOLOGICAL SAFETY CABINET MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–SEPTEMBER 2026 164.
TABLE 186 BIOLOGICAL SAFETY CABINET MARKET: DEALS, JANUARY 2023–SEPTEMBER 2026 165.
TABLE 187 BIOLOGICAL SAFETY CABINET MARKET: EXPANSION, JANUARY 2023–SEPTEMBER 2026 165.
TABLE 188 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 166.
TABLE 189 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED 167.
TABLE 190 KEWAUNEE SCIENTIFIC CORPORATION: COMPANY OVERVIEW 169.
TABLE 191 KEWAUNEE SCIENTIFIC CORPORATION: PRODUCTS OFFERED 170.
TABLE 192 KEWAUNEE SCIENTIFIC CORPORATION: DEALS, JANUARY 2023–SEPTEMBER 2026 171.
TABLE 193 ESCO LIFESCIENCES GROUP: COMPANY OVERVIEW 172.
TABLE 194 ESCO LIFESCIENCES GROUP: PRODUCTS OFFERED 172.
TABLE 195 ESCO LIFESCIENCES GROUP: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–SEPTEMBER 2026 174.
TABLE 196 ESCO LIFESCIENCES GROUP: DEALS, JANUARY 2023–SEPTEMBER 2026 174.
TABLE 197 ESCO LIFESCIENCES GROUP: EXPANSIONS, JANUARY 2023–SEPTEMBER 2026 175.
TABLE 198 LABCONCO CORPORATION: COMPANY OVERVIEW 176.
TABLE 199 LABCONCO CORPORATION: PRODUCTS OFFERED 176.
TABLE 200 LABCONCO CORPORATION: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–SEPTEMBER 2026 177.
TABLE 201 THE BAKER COMPANY, INC.: COMPANY OVERVIEW 179.
TABLE 202 THE BAKER COMPANY, INC.: PRODUCTS OFFERED 179.
TABLE 203 THE BAKER COMPANY, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–SEPTEMBER 2026 180.
TABLE 204 GERMFREE LABORATORIES, INC.: COMPANY OVERVIEW 181.
TABLE 205 GERMFREE LABORATORIES, INC.: PRODUCTS OFFERED 181.
TABLE 206 CRUMA: COMPANY OVERVIEW 183.
TABLE 207 CRUMA: PRODUCTS OFFERED 183.
TABLE 208 AIR SCIENCE USA LLC: COMPANY OVERVIEW 185.
TABLE 209 AIR SCIENCE USA LLC: PRODUCTS OFFERED 185.
TABLE 210 BERNER INTERNATIONAL GMBH: COMPANY OVERVIEW 186.
TABLE 211 BERNER INTERNATIONAL GMBH: PRODUCTS OFFERED 186.
TABLE 212 LABOGENE: COMPANY OVERVIEW 188.
TABLE 213 LABOGENE: PRODUCTS OFFERED 188.
TABLE 214 BIOLAB SCIENTIFIC LTD.: COMPANY OVERVIEW 189.
TABLE 215 BIOLAB SCIENTIFIC LTD.: PRODUCTS OFFERED 189.
TABLE 216 LAMSYSTEMS CC: COMPANY OVERVIEW 191.
TABLE 217 LAMSYSTEMS CC: PRODUCTS OFFERED 191.
TABLE 218 BIOLOGICAL SAFETY CABINET MARKET: RISK ASSESSMENT 211.